Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase NA 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 5Leukemia, Myeloid, Acute 4Neoplasm, Residual 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Biphenotypic, Acute 1Ataxia Telangiectasia 1Ataxia 1

Interventions

blinatumomab 3Blood Specimen Collection 2Azacitidine 2venetoclax 1ivosidenib 1gilteritinib 1daratumumab 1avapritinib 1Transplantation 1Radiosurgery 1Neoadjuvant Therapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lenalidomide 1Interferon alpha-2 1Inotuzumab Ozogamicin 1Idarubicin 1High-Throughput Nucleotide Sequencing 1Daunorubicin 1Cytarabine 1Control Groups 1Consolidation Chemotherapy 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neoplasm, Residual × Daunorubicin × Clear all
NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
120 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡